

In an ethically charged first, Chinese researchers have used gene editing to modify human embryos obtained from an in-vitro fertilization clinic.



The 16-person scientific team, based at the Sun Yat-Sen University in Guangzhou, China, set out to see whether it could correct the gene defect that causes beta-thalassemia, a blood disease, by editing the DNA of fertilized eggs.



READ MORE ON MIT TECHNOLOGY REVIEW



Ref: CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein & Cell (2015) | DOI:10.​1007/​s13238-015-0153-5